MedPath

The Effect of β-hydroxy-β-methylbutyrate Supplementation on Physical Capacity and Body Composition in Trained Athletes

Phase 3
Completed
Conditions
Sport
Supplements
Supplementation
Interventions
Dietary Supplement: β-hydroxy-β-methylbutyrate and a placebo supplementation
Registration Number
NCT03028649
Lead Sponsor
Poznan University of Medical Sciences
Brief Summary

The purpose of this study was to verify the effect of 12-week with β-hydroxy-β-methylbutyrate (HMB) and a placebo (PLA) supplementation on body composition, anaerobic and aerobic capacity, as well as concentrations of the selected biochemical blood markers in trained athletes, in a randomised, double-blind, placebo-controlled crossover trial.

Detailed Description

The effect of HMB supplementation is of great interest in sport. In view of the inconclusive character of the results of the studies conducted to date and of a relatively low number of studies investigating the effectiveness of HMB supplementation over a longer period on a large population of trained athletes, the aim of this study was to verify the effect of 12-week with HMB and a placebo supplementation on body composition, anaerobic and aerobic capacity, as well as concentrations of the selected biochemical blood markers in trained athletes, in a randomised, double-blind, placebo-controlled crossover trial.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
58
Inclusion Criteria
  • written consent to participate,
  • male
  • a current medical clearance to practice sports,
  • training experience: at least 5 years,
  • minimum of 6 workout sessions a week (minimum 3 in the practiced sports discipline).
Exclusion Criteria
  • current injury,
  • any health-related contraindication,
  • declared general feeling of being unwell,
  • unwilling to follow the study protocol.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Placebo (maltodextrin)β-hydroxy-β-methylbutyrate and a placebo supplementationGroup taking oral supplementation with placebo (maltodextrin). A single capsule contained 1000 mg of maltodextrin. Interventions: The experimental procedure for each athlete included a 12-week placebo administration - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day. Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced.
β-hydroxy-β-methylbutyrate (HMB)β-hydroxy-β-methylbutyrate and a placebo supplementationGroup taking oral supplementation with calcium salt of β-hydroxy-β-methylbutyric acid produced by Olimp Laboratories. A single capsule contained 1250 mg Ca-HMB, which corresponds to 1000 mg of β-hydroxy-β-methylbutyrate. Interventions: The experimental procedure for each athlete included a 12-week HMB supplementation - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day. Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced.
Primary Outcome Measures
NameTimeMethod
Changes of aerobic capacity after HMB supplementationBaseline and after 12 weeks
Changes of body composition indices after HMB supplementationBaseline and after 12 weeks

Analysis of the fat mass and fat free mass

Changes of aerobic capacity after placebo treatmentBaseline and after 12 weeks
Changes of creatine kinase and lactate dehydrogenase activity in blood after HMB supplementationBaseline and after 12 weeks
Changes of testosterone, cortisol and lactate levels in blood after HMB supplementationBaseline and after 12 weeks
Changes of anaerobic capacity after placebo treatmentBaseline and after 12 weeks
Changes of testosterone, cortisol and lactate levels in blood after placebo treatmentBaseline and after 12 weeks
Changes of body composition indices after placebo treatmentBaseline and after 12 weeks

Analysis of the fat mass and fat free mass

Changes of creatine kinase and lactate dehydrogenase activity in blood after placebo treatmentBaseline and after 12 weeks
Changes of anaerobic capacity after HMB supplementationBaseline and after 12 weeks
Secondary Outcome Measures
NameTimeMethod
Statistical evaluation of the significance of differences between the changes in body composition (fat mass and fat free mass)1 year
Statistical evaluation of the significance of differences between the changes in creatine kinase and lactate dehydrogenase activity and testosterone, cortisol and lactate levels in blood1 year
Statistical evaluation of the significance of differences between the changes in aerobic capacity indices1 year
Statistical evaluation of the significance of differences between the changes in anaerobic capacity indices1 year

Trial Locations

Locations (1)

Poznan University of Life Sciences, ul.Wojska Polskiego 31

🇵🇱

Poznan, Wielkopolska, Poland

© Copyright 2025. All Rights Reserved by MedPath